Aristotle University Of Thessaloniki (AUTH)
Μελέτη των γενετικών πολυμορφισμών των ανθρώπινων λευκοκυτταρικών αντιγόνων σε ασθενείς με διάχυτο λέμφωμα από μεγάλα Β-κύτταρα
Abstract
dc:descriptionPolymorphisms of the human leukocyte antigens (HLA) gene locus appear to be associated with the risk of developing malignant neoplasms, including lymphomas. Among the factors implicated in their pathogenesis, the genetic background is considered to play a critical and determining role. The aim of this study is to determine whether HLA polymorphisms are associated with the risk of developing diffuse large B-cell lymphoma (DLBCL) and whether the polymorphisms are related to overall survival (OS) and progression free survival (PFS). During the study, some patients developed sequential lymphoma. Based on this observation, an attempt was made to investigate HLA polymorphisms in a group of patients with DLBCL and sequential lymphoma. HLA class I (HLA-A, HLA-B, HLA-C) and class II (HLA-DRB1, HLA-DQB1) alleles were typed in 60 patients with DLBCL, who constituted our patient group, and in 236 healthy adult donors from the Northern Greece bone marrow bank, who constituted our control group. HLA typing was performed with molecular methods, Sequence - Specific Oligonucleotide HLA (SSO) and Sequence - Specific Primer HLA (SSP). The phenotypic frequencies of HLA-A, HLA-B, HLA-C, HLA-DRB1 and HLA-DQB1 between the two groups (patients and control) were compared using the 2-sided Fisher's exact test. Results with a p value < 0.05 were considered statistically significant. Odds ratios with 95% confidence intervals were calculated to further strengthen the results. The 2-sided Fisher's exact test was also applied to alleles found in only one of the two groups, while the odds ratios along with the confidence intervals were corrected using the Haldane-Anscombe method. Typing of HLA class I and class II alleles were also performed in the group of sequential lymphomas consisting of 8 individuals who developed sequential lymphoma, in whom DLBCL was either the primary or the second lymphoma. Among the HLA polymorphisms studied, the frequency of the HLA-C*12 allele was significantly lower in patients with DLBCL compared to the control group (3.33% vs. 17.9%, OR = 0.16, 95% CI: 0.04-0.44). Survival analysis revealed that the presence of HLA-C*12 was not associated with improved or worsened OS and PFS. No statistically significant correlations were observed in the phenotypic frequencies of HLA-A, HLA-B, HLA-DQB1 and HLA-DRB1 between the control and DLBCL groups. In the group of sequential lymphomas, it was found that the HLA-DQB1*03:01(DQ7) alleles were common in four patients. Our results indicate the role of HLA polymorphisms in the risk of developing DLBCL in both groups of patients. However, due to the relatively small number of participants, further studies are needed to consolidate our findings and ascertain the clinical implications of these genetic variants in the management and prognosis of patients with DLBCL.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Diamanti, Ioanna
- Διαμαντή, Ιωάννα
Subjects
dc:subject × 14- Ανθρώπινα λευκοκυτταρικά αντιγόνα
- Διάχυτο λέμφωμα από μεγάλα Β κύτταρα
- Γενετικοί πολυμορφισμοί
- Διαδοχικό/δεύτερο λέμφωμα
- Human Leukocyte Αntigens
- Diffuse Large B-Cell Lymphoma, DLBCL
- Genetic polymorphisms
- Sequential Lymphoma
- Βασική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Ανοσολογία
- Basic Medicine
- Medical and Health Sciences
- Immunology
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/59838